These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24275154)

  • 41. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL; Siekmann J; Schwarz HP
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The phenotypic and genotypic diagnosis of three Chinese patients with von Willebrand disease].
    Jiang LL; Cao YN; Wang XF; Ding QL; Xu GQ; Zhang LW; Dai J; Lu YL; Wang HL; Xi XD
    Zhonghua Nei Ke Za Zhi; 2012 Oct; 51(10):788-92. PubMed ID: 23290978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. von Willebrand disease R1374C: type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia).
    Penas N; Pérez-Rodríguez A; Torea JH; Lourés E; Noya MS; López-Fernández MF; Batlle J
    Am J Hematol; 2005 Nov; 80(3):188-96. PubMed ID: 16247740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Idiopathic pulmonary arterial hypertension - a unrecognized cause of high-shear high-flow haemostatic defects (otherwise referred to as acquired von Willebrand syndrome) in children.
    Pelland-Marcotte MC; Humpl T; James PD; Rand ML; Bouskill V; Reyes JT; Bowman ML; Carcao MD
    Br J Haematol; 2018 Oct; 183(2):267-275. PubMed ID: 30141279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of von Willebrand disease in women with iron deficiency anaemia and menorrhagia in Taiwan.
    Chen YC; Chao TY; Cheng SN; Hu SH; Liu JY
    Haemophilia; 2008 Jul; 14(4):768-74. PubMed ID: 18498402
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.
    Favaloro EJ; Thom J; Patterson D; Just S; Baccala M; Dixon T; Meiring M; Koutts J; Rowell J; Baker R
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):475-83. PubMed ID: 19584715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S; Mezzasoma AM; Leone M; Gresele P
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
    Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Laboratory diagnosis of congenital von Willebrand disease.
    Budde U; Drewke E; Mainusch K; Schneppenheim R
    Semin Thromb Hemost; 2002 Apr; 28(2):173-90. PubMed ID: 11992241
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pediatric Acquired von Willebrand Syndrome in Cardiopulmonary Disorders: Do Laboratory Abnormalities Predict Bleeding Risk?
    Hashmi SK; Velasquez MP; Yee DL; Hui SK; Mahoney D; Srivaths LV
    J Pediatr Hematol Oncol; 2017 Mar; 39(2):121-125. PubMed ID: 28060126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
    Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).
    Tosetto A; Rodeghiero F; Castaman G; Goodeve A; Federici AB; Batlle J; Meyer D; Fressinaud E; Mazurier C; Goudemand J; Eikenboom J; Schneppenheim R; Budde U; Ingerslev J; Vorlova Z; Habart D; Holmberg L; Lethagen S; Pasi J; Hill F; Peake I
    J Thromb Haemost; 2006 Apr; 4(4):766-73. PubMed ID: 16634745
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of acquired von Willebrand syndrome with AL amyloidosis.
    Kos CA; Ward JE; Malek K; Sanchorawala V; Wright DG; O'Hara C; Connors L; Skinner M; Seldin DC
    Am J Hematol; 2007 May; 82(5):363-7. PubMed ID: 17205535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Diagnostic strategies for detection of the von Willebrand syndrome].
    Eller T; Mayer J; Bomhard M; Keller F
    Beitr Infusionsther; 1992; 30():268-71. PubMed ID: 1284714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence and spectrum of von Willebrand disease from western India.
    Trasi S; Shetty S; Ghosh K; Mohanty D
    Indian J Med Res; 2005 May; 121(5):653-8. PubMed ID: 15937368
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of transcutaneous aortic valve implantation on aortic valve disease-related hemostatic disorders involving von Willebrand factor.
    Caspar T; Jesel L; Desprez D; Grunebaum L; Samet H; Trinh A; Petit-Eisenmann H; Kindo M; Ohlmann P; Morel O
    Can J Cardiol; 2015 Jun; 31(6):738-43. PubMed ID: 25935884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol.
    Hillarp A; Stadler M; Haderer C; Weinberger J; Kessler CM; Römisch J
    J Thromb Haemost; 2010 Oct; 8(10):2216-23. PubMed ID: 20727070
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Haemostatic abnormalities in treatment-naïve patients with Type 1 Gaucher's disease.
    Mitrovic M; Antic D; Elezovic I; Janic D; Miljic P; Sumarac Z; Nikolic T; Suvajdzic N
    Platelets; 2012; 23(2):143-9. PubMed ID: 21767238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.